Search Results
Your search for ,had matches 18605 pages
Showing 17351 - 17400ASH 2014: T-Cell Acute Lymphoblastic Leukemia Outcomes Excellent, Even for 'Poor-Risk' Group
Outcomes in children with T-cell acute lymphoblastic leukemia (ALL), which has traditionally been considered a poor-prognosis cancer, are better than expected, even for the early thymic precursor (ETP) phenotype, according to investigators from the Children’s Oncology Group (COG) who...
ASH 2014: High Hopes for AG-221 in Advanced Leukemia
Although the data are preliminary, single-agent AG-221 therapy targeted to the IDH2 mutation holds great promise as a nonchemotherapy approach for the treatment of advanced hematologic malignancies, including relapsed/refractory acute myelogenous leukemia (AML) and untreated AML. The findings were...
Daniel F. Hayes, MD, FASCO, Elected ASCO President for 2016-2017 Term
Daniel F. Hayes, MD, FASCO, has been elected President of the American Society of Clinical Oncology (ASCO) for the term beginning in June 2016. He will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2015. “I'm honored to be elected incoming President of...
ASH 2014: Ibrutinib Demonstrates Clinical Activity in Relapsed or Refractory Multiple Myeloma
According to new data reported at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition, ibrutinib (Imbruvica) demonstrated antitumor activity both as a single agent and in combination with dexamethasone in heavily pretreated patients with relapsed or relapsed/refractory...
ASH 2014: Pediatric Leukemia Treatment Regimens Lead to Improved Outcomes in Adolescents, Young Adults
Results from a large prospective study suggest that children and young adults with acute lymphocytic leukemia (ALL) may respond better to a chemotherapy regimen pioneered in pediatric patients. The findings were presented at the 56th American Society of Hematology (ASH) Annual Meeting and...
ASH 2014: Blinatumomab Achieves Complete Molecular Responses in Majority of B-Cell Leukemia Patients
Results from the international phase II BLAST study show that one cycle of blinatumomab (Blincyto) immunotherapy achieved complete minimal residual disease response in 78% of patients with precursor B-cell acute lymphoblastic leukemia (ALL). Complete minimal residual disease response was...
ASH 2014: PD-1 Blockade Moves Into Hematology
The promise of the programmed death receptor-1 (PD-1) inhibitors seen in solid tumors, especially melanoma, may hold true for at least one hematologic malignancy, according to studies presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition. At a press briefing,...
ASH 2014: Post-Transplant Brentuximab Vedotin Improves Progression-Free Survival in Hodgkin Lymphoma Patients
In Hodgkin lymphoma patients at risk for disease progression following autologous stem cell transplant, early consolidation post-transplant with brentuximab vedotin (Adcetris) significantly improved progression-free survival compared with placebo in the phase III AETHERA trial. The findings were...
ASH 2014: HIV-Related Lymphoma Can Be Safely Treated With Autologous Hematopoietic Cell Transplant
Patients with human immunodeficiency virus (HIV)-related relapsed/refractory lymphoma can safely undergo autologous hematopoietic cell transplant, according to results of a phase II multicenter trial. At many centers, patients with HIV-related lymphoma are currently excluded from this potentially...
ASH 2014: Strong Showing for Anti-CD38 Monoclonal Antibodies in Myeloma
An investigational new class of drugs, the anti-CD38 monoclonal antibodies, could be the next blockbuster agents in multiple myeloma, experts in this malignancy predicted at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition. Anti-CD38 antibodies target multiple myeloma...
ASH 2014: Carfilzomib-Based Triplet Yields ‘Unprecedented’ Duration of Remission in Relapsed Myeloma
The phase III global ASPIRE trial documented an “unprecedented” duration of remission in relapsed multiple myeloma patients receiving carfilzomib (Kyprolis) plus a standard-of-care doublet, according to A. Keith Stewart, MD, of the Mayo Clinic in Scottsdale, Arizona, who presented the...
‘Wound Response’ of Cancer Stem Cells May Explain Chemoresistance in Bladder Cancer
A novel mechanism—similar to how normal tissue stem cells respond to wounding—might explain why bladder cancer stem cells actively contribute to chemoresistance after multiple cycles of chemotherapy drug treatment. Targeting this “wound response” of cancer stem cells can...
Intensified Chemotherapy Based on Tumor Marker Decline May Improve Progression-Free Survival in Patients With Poor-Prognosis Germ Cell Tumors
In the phase III GETUG 13 trial reported in The Lancet Oncology, Fizazi et al found that treatment intensification based on early tumor marker decline resulted in a numeric and borderline statistically significant improvement in progression-free survival in patients with poor-prognosis germ cell...
Telomere Length Genes Are Associated With Melanoma Risk
Longer telomeres have been associated with increased risk of melanoma. In a GenoMEL Consortium genome-wide association study reported in the Journal of the National Cancer Institute, Iles et al found that several single-nucleotide polymorphisms (SNPs) previously associated with leukocyte telomere...
No Survival Difference but Greater Morbidity With Etoposide/Cisplatin vs Carboplatin/Paclitaxel With Concurrent Radiotherapy for Stage III NSCLC
In an analysis of Veterans Health Administration data reported in the Journal of Clinical Oncology, Santana-Davila et al found that etoposide/cisplatin resulted in no overall survival difference but greater morbidity compared with carboplatin/paclitaxel used concurrently with radiotherapy in...
Approximately 4% of New Cancers Worldwide Attributed to High BMI
In a population-based study reported in The Lancet Oncology, Arnold et al estimated that 3.6% of all new cancers worldwide in 2012 were attributable to high body mass index (BMI). The proportions of such cases were greater in women than in men and in highly developed vs less-developed countries....
FDA Approves Ruxolitinib to Treat Patients With Polycythemia Vera
The U.S. Food and Drug Administration (FDA) today approved a new use for ruxolitinib (Jakafi) to treat patients with polycythemia vera, a chronic type of bone marrow disease. Ruxolitinib, a JAK inhibitor, is the first drug approved by the FDA for this condition. Polycythemia vera occurs when too...
Surveillance Guidelines Miss 30% of Renal Cell Carcinoma Recurrences After Nephrectomy
In a study reported in the Journal of Clinical Oncology, Stewart et al found that 30% or more of renal cell carcinoma recurrences were missed using National Comprehensive Cancer Network (NCCN) and American Urological Association (AUA) guidelines for surveillance after surgery for renal cell...
FDA Approves Blinatumomab to Treat Rare Form of Acute Lymphoblastic Leukemia
The U.S. Food and Drug Administration (FDA) today granted accelerated approval to blinatumomab (Blincyto) for the treatment of patients with Philadelphia chromosome–negative, relapsed or refractory precursor B-cell acute lymphoblastic leukemia (B-cell ALL). Blinatumomab is a bispecific...
Dacomitinib Shows Activity in First-Line Treatment of Patients With Clinically or Molecularly Selected Advanced NSCLC
In a phase II trial reported in The Lancet Oncology, Jänne et al found that the pan-HER inhibitor dacomitinib was active in first-line treatment of patients with advanced non–small cell lung cancer (NSCLC) with EGFR mutations or clinical characteristics associated with response to EGFR...
RSNA Awards Gold Medal to Three Leaders in Radiology
The Radiological Society of North America (RSNA) awarded the Gold Medal, the organization’s highest honor, to three individuals at the RSNA 100th Scientific Assembly and Annual Meeting: Gary J. Becker, MD, of Tucson; Allen S. Lichter, MD, FASCO, of Alexandria, Virginia; and Etta D. Pisano,...
Risk-Based Screening Misses Over 75% of Invasive Breast Cancers in Women in Their 40s
A study of breast cancers detected with screening mammography found that strong family history and dense breast tissue were commonly absent in women between the ages of 40 and 49 diagnosed with breast cancer. Results of the study were presented today at RSNA 2014, the annual meeting of the...
Long-Term Diabetes Associated With Increased Mortality in Pancreas Cancer
In a study reported in the Journal of Clinical Oncology, Yuan et al found that pancreas cancer patients with diabetes of more than 4 years’ duration at diagnosis had significantly poorer survival compared with nondiabetic patients. Study Details The study involved data from 1,006 patients...
DNA Vaccine Targeting Mammaglobin-A Produces Robust Immune Response in Metastatic Breast Cancer
In a phase I study, a DNA vaccine targeting the breast cancer–associated antigen mammaglobin-A (MAM-A) was found to be safe and effective in eliciting immune responses in women with metastatic breast cancer. Preliminary evidence also suggests that the vaccine improved progression-free...
Despite Popularity of Alternative Medicine, Most U.S. Oncologists Do Not Discuss Herb and Supplement Use With Their Patients
Available data indicate that a majority of cancer patients use complementary and alternative medicine. In a study reported in the Journal of Clinical Oncology, Lee et al found that oncologists responding to a survey on herb and supplement use did not discuss herb and supplement use with most of...
Anti-CD19 Bispecific T Cell Engager Blinatumomab Shows Activity in Relapsed/Refractory B-Precursor ALL
In a phase II study reported in the Journal of Clinical Oncology, Topp et al found that the bispecific T-cell engager (BiTE) antibody blinatumomab produced a high response rate in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). BiTEs induce a transient cytolytic ...
More Than 40% of U.S. Women Have Mammographically Dense Breasts
In a study reported in the Journal of the National Cancer Institute, Sprague et al found that more than 40% of U.S. women have mammographically dense breasts, with the prevalence being inversely proportional to age and body mass index (BMI). As noted by the authors: “National legislation is...
Addition of Vosaroxin to Cytarabine Demonstrates Antileukemic Activity in Relapsed or Refractory Acute Myeloid Leukemia
In a phase Ib/II study of patients with relapsed or refractory acute myeloid leukemia (AML), the addition of vosaroxin to cytarabine demonstrated antileukemic activity and an acceptable risk-benefit profile, according to a study by Lancet et al in Haematologica. Based on the findings from this...
Benefit of Extended Rituximab Exposure in Poor-Prognosis Elderly Patients With Diffuse Large B-Cell Lymphoma
In the phase II SMARTE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group reported in the Journal of Clinical Oncology, Pfreundschuh et al found that extended rituximab (Rituxan) exposure in patients aged > 60 years with poor-prognosis diffuse large B-cell lymphoma was...
Low Risk of Breast Cancer After Ovarian Cancer in Women With BRCA Mutation
In a retrospective single-institution study reported in JAMA Surgery, Gangi et al found a low risk of breast cancer after diagnosis of ovarian cancer in women harboring BRCA mutations. The study involved 364 women who had BRCA mutation testing for stage I to IV epithelial ovarian...
RTOG 0129 Long-Term Results: No Differences in Survival or Toxicity With Accelerated vs Standard Fractionation Plus Cisplatin in Head and Neck Cancer
As reported in the Journal of Clinical Oncology by Nguyen-Tan et al, long-term follow-up in the phase III Radiation Therapy Oncology Group (RTOG) 0129 trial indicates no difference in overall survival or late toxicity with use of accelerated vs standard radiation therapy plus cisplatin in patients...
Adult Survivors of Retinoblastoma Experience Few Cognitive or Social Setbacks
Adult survivors of retinoblastoma, a type of eye cancer that usually develops in early childhood, have few cognitive or social problems decades following their diagnosis and treatment, according to a study by Brinkman et al published in Cancer. The findings offer good news for patients, but the...
High-Dose Interleukin-2 Effective in Metastatic Renal Cell Cancer Pretreated With VEGF-Targeted Therapies
High-dose interleukin-2 can be effective in selected metastatic renal cell cancer patients pretreated with VEGF-targeted agents, according to research presented recently at the ESMO Symposium on Immuno-Oncology in Geneva (Abstract 4O). “Despite the wide and increasing range of therapies...
Cigarette Smoking Before Diagnosis of First Cancer Is Associated With Increased Risk of Second Cancers
In a study reported in the Journal of Clinical Oncology, Shiels et al found that prediagnostic smoking among survivors of stage I lung cancer or bladder, kidney, or head/neck cancer was associated with increased risk of second lung, bladder, kidney, and head and neck cancer. Study Details The...
Improved Overall Survival in Metastatic Melanoma With First-Line Dabrafenib Plus Trametinib
In a phase III study reported in The New England Journal of Medicine, Robert et al found that the combination of the BRAF inhibitor dabrafenib (Tafinlar) plus the MEK inhibitor trametinib (Mekinist) significantly improved overall survival compared with the BRAF inhibitor vemurafenib (Zelboraf) in...
Two- vs One-Unit Cord Blood Transplantation Does Not Improve 1-Year Overall Survival in Children and Adolescents With Hematologic Cancers
In a phase III trial reported in The New England Journal of Medicine, Wagner et al found that use of two units vs one unit of umbilical cord blood in hematopoietic stem cell transplantation did not improve 1-year overall survival in children and adolescents with hematologic cancers. Use of...
Immune Checkpoint Inhibitors May Work in Brain Cancers
New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today at the ESMO Symposium on Immuno-Oncology 2014 in Geneva (Abstract 1O). The novel research shows that brain metastases of tumor infiltrating lymphocytes, providing an immunoactive...
Advanced-Practice Nurse Telephone Counseling Improves Rate of Cardiomyopathy Screening in At‑Risk Adult Survivors of Pediatric Cancer
In the ECHOS trial reported in the Journal of Clinical Oncology, Hudson et al found that the addition of two tailored telephone counseling sessions by an advanced-practice nurse to a mailed personalized survivorship care plan including cardiac screening recommendations resulted in a greater than...
Novel Genomic Signature Predicts Postcystectomy Recurrence in High-Risk Bladder Cancer
As reported in the Journal of the National Cancer Institute, Mitra et al have identified a novel genomic-based signature that improves prediction of postcystectomy recurrence in patients with high-risk bladder cancer. Use of the signature could help guide selection of patients for adjuvant therapy...
Exposure to Hookah Smoke Doubles Benzene Uptake, Potentially Increasing Risk for Leukemia
Findings from a new study show that hookah smokers and nonsmokers exposed to hookah (or waterpipe) secondhand tobacco smoke at social events in hookah lounges and in private homes had significant increases in uptake of benzene, a leukemogen that causes lymphohematopoietic cancers, especially acute...
Researchers Identify Biomarker of Response to New Ovarian Cancer Drug
Researchers have found a way to identify which ovarian cancer patients are likely to respond well to a new anticancer drug called rucaparib. Previous clinical trials have shown that women with platinum-sensitive tumors with BRCA1/2 mutations respond well to rucaparib. In new findings presented...
PAM50 Risk of Recurrence Score Helps Predict Late Distant Recurrence After 5 Years of Endocrine Treatment for Breast Cancer
In a combined analysis of outcomes in the translational research cohort of the Arimidex, Tamoxifen Alone or in Combination trial (TransATAC) and the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG 8) trial reported in the Journal of Clinical Oncology, Sestak and colleagues found that the ...
About 25% of Patients Undergoing Breast-Conservation Surgery for Stage 0 to II Carcinoma Have Subsequent Surgery
“Approximately one-fourth of all patients who undergo initial breast-conservation surgery for breast cancer will have a subsequent operative intervention,” concluded a study published online in JAMA Surgery. “The rate of repeat surgeries varies by patient, tumor, and facility...
Nivolumab Improves Overall and Progression-Free Survival vs Dacarbazine in Previously Untreated Advanced Melanoma Without BRAF Mutation
In a phase III trial reported in The New England Journal of Medicine, Robert et al found that the PD-1 immune-checkpoint–inhibitor antibody nivolumab significantly increased overall survival, progression-free survival, and objective response rate compared with dacarbazine in patients with...
Galeterone Shows Activity in Variant Form of Castration-Resistant Prostate Cancer
Results from the ARMOR2 of the anticancer drug galeterone shows that it is successful in lowering prostate-specific antigen (PSA) levels in men with a variant form castration-resistant prostate cancer. The findings, presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer...
Patients With Advanced Papillary Kidney Cancer Respond Well to Bevacizumab/Erlotinib Combination Therapy
Researchers have found that patients with an advanced form of kidney cancer, for which there is no standard treatment and a very poor prognosis, respond well to a combination of two existing anticancer drugs. The combination of bevacizumab (Avastin) and erlotinib (Tarceva) produced excellent...
IDH1 Inhibitor Demonstrates Anticancer Activity in Advanced Leukemia
A phase I trial of the first drug designed to inhibit the cancer-causing activity of a mutated enzyme known as isocitrate dehydrogenase (IDH) 1, which is involved in cell metabolism, has shown clinical activity in patients with advanced acute myeloid leukemia (AML) with the IDH1 mutation. The...
RTOG Pooled Analysis Shows Good Long-Term Outcomes After Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer
In a pooled analysis of prospective Radiation Therapy Oncology Group (RTOG) studies reported in the Journal of Clinical Oncology, Mak et al found good long-term outcomes with bladder-preserving combined-modality therapy for muscle-invasive bladder cancer. Study Details The analysis included 468...
High Rate of Tumor Marker Assessment in Older Early-Stage Breast Cancer Survivors
Current guidelines discourage tumor marker assessment in surveillance of nonmetastatic breast cancer. In a study reported in the Journal of Clinical Oncology, Ramsey et al found that > 40% of Medicare patients with early-stage breast cancer had at least one tumor marker assessment and that...
Proton Radiotherapy Safe and Effective in Pediatric Rhabdomyosarcoma
In a phase II study reported in the Journal of Clinical Oncology, Ladra et al found that proton radiotherapy was a safe and effective treatment in pediatric rhabdomyosarcoma. Proton radiotherapy can substantially reduce radiotherapy doses to normal tissue compared with conventional photon...
